ACE inhibitors were associated with improving survival in PC patients, but only during their first three years of survival in which they experienced mortality risk reductions of 13% in general and 17% among non-metastatic patients not resected – a subgroup likely representing locally advanced PC patients that, in our study, did not appear to benefit as much as others from ARB exposure. The gene discussed is ACE; the disease is pachyonychia congenita.